CycloLab’s submission to InnoCentive Challenge 9934291 – New Technologies to Prevent the Transmission of Coronavirus led to a favorable evaluation.
Obesity has become a worldwide health crisis and is associated with a plethora of comorbidities. Cardiovascular disease (CVD) and type
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
Scientific Report published on the recent results of Faculty of Dentistry, National University of Singapore.  Resveratrol (RES) is a
There are two possible mechanisms behind the ototoxicity of 2-hydroxypropyl-β-cyclodextrin (HPBCD) treatment. One is : the possible interaction of HPBCD
The scientists at University of Michigan Medical Center, Ann Arbor, MI published on a new application of hydroxypropyl beta-cyclodextrin (HPβCD)
Cyclo Therapeutics, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C
ADAMA MAKHTESHIM LTD. (Israel) filed a PCT patent application (WO2020084572) that was recently published. The invention relates to preparation and use
Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.